title: Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks.
authors.affiliation: Department of Dermatology, Baylor College of Medicine, Houston, Texas. Electronic address: ymhuang@bcm.edu.
authors.forename: Yuan Yu Michael
authors.initials: YYM
authors.lastname: Huang
authors.affiliation: Department of Dermatology, Baylor College of Medicine, Houston, Texas.
authors.forename: Jennifer Shuley
authors.initials: JS
authors.lastname: Ruth
authors.affiliation: Department of Dermatology, Baylor College of Medicine, Houston, Texas.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Hsu
mesh_terms: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D011565:Psoriasis
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C555450:secukinumab